Oncology and Hematology

Episodes 129-144 of 390

Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
1.00 program credit
- Nicoletta Colombo, MD
- Susana Campos, MD, MPH
1.00 program credit
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
MinuteCE®
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
0.75 program credits
- Rana McKay, MD
0.75 program credits
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
1.25 program credits
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 program credits
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Project Oncology®
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Project Oncology®
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
- Heather Greenlee, ND, PhD, MPH
The Potential Link Between COVID-19 and Cancer Regression
The Potential Link Between COVID-19 and Cancer Regression
Clinician's Roundtable
The Potential Link Between COVID-19 and Cancer Regression
- Ankit Bharat, MD
The Future of ITP Care: Exploring New Treatments
The Future of ITP Care: Exploring New Treatments
Project Oncology®
The Future of ITP Care: Exploring New Treatments
- Michele Lambert, MD, MSTR
Understanding iMCD Through RNA Sequencing
Understanding iMCD Through RNA Sequencing
Project Oncology®
Understanding iMCD Through RNA Sequencing
- Michael Gonzalez, PhD, MSc
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
Project Oncology®
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
- Jacob Sands, MD
- Marina Garassino, MD
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Project Oncology®
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
- Heather A. Parsons, MD, MPH
Diagnosing Castleman Disease: Key Considerations
Diagnosing Castleman Disease: Key Considerations
Project Oncology®
Diagnosing Castleman Disease: Key Considerations
- Mateo Bustamante
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Project Oncology®
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
- Joshua Brandstadter, MD, PhD, MSc
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy
Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy
Project Oncology®
Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Hope S. Rugo, MD, FASCO
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit